OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Clinical Dermatology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	280
Alcohol and Smoking Cessation as Potential Modulators for Smoking-Associated Psoriasis Risk in Postmenopausal Women: The Women’s Health Initiative	187
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	125
Prognostic Biomarkers in Evolving Melanoma Immunotherapy	104
Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions	103
The Current State of Systemic Therapy of Metastatic Uveal Melanoma	94
Disease Duration in Patients Recruited to Psoriasis Phase III Trials: A Systematic Review	87
The Burden of Pediatric Psoriasis: A Systematic Review	77
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study	75
Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma	74
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study	73
Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials	70
Deciphering the Etiologies of Adult Erythroderma: An Updated Guide to Presentations, Diagnostic Tools, Pathophysiologies, and Treatments	70
Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know	70
Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data	65
Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review	65
Patient-Reported Outcome Measures and Their Clinical Applications in Dermatology	64
Agreement Between Nail Psoriasis Severity Index Scores by a Convolutional Neural Network and Dermatologists: A Retrospective Study at an Academic New York City Institution	64
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroi	61
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks	59
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?	57
Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”	54
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion	53
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation	53
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study	51

Skin Cancer in Solid Organ Transplant Recipients: A Review	50
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment	49
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry	49
48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients	48
Disease Modification in Psoriasis: Future Prospects for Long-Term Remission	48
Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review	47
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives	46
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management	46
Dissecting Cellulitis of the Scalp: Current Insights and Therapeutic Advances	44
Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!	43
A Practice Approach to Acne Fulminans in Adolescents	43
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis	41
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment	41
Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis	39